It is provided processes for generating a therapeutic concentrated phospholipid composition from raw krill oil containing high content of free fatty acids. Particularly it is provided a process producing a concentrated phospholipid composition comprising the steps of: fractionating a raw hill oil (RKO) containing at least 7% of free fatty acids (FFA) obtaining a fraction enriched in phospholipids and an undesired layer; and separating said fraction enriched in phospholipids from the undesired layer, producing the therapeutic concentrated phospholipid composition with a yield of at least 30%.

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

The present invention provides, inter alia, methods and compositions that are useful in the treatment of cancer.

The present invention provides, inter alia, methods and compositions that are useful in the treatment of cancer.

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

Here, the present inventors describe novel methods and compositions to reduce protein misfolding, the formation of protein aggregates, as well as the degradation of previously formed protein aggregates, for example by separating fibrils back into protofilaments. Additional aspects of the invention include therapeutic uses of lipid bilayers to rescue misfolded proteins in Alzheimer's and other protein misfolding diseases.

Here, the present inventors describe novel methods and compositions to reduce protein misfolding, the formation of protein aggregates, as well as the degradation of previously formed protein aggregates, for example by separating fibrils back into protofilaments. Additional aspects of the invention include therapeutic uses of lipid bilayers to rescue misfolded proteins in Alzheimer's and other protein misfolding diseases.

Disclosed is a method for treating cancer in patient in need thereof comprising administering a therapeutically effective amount of a nucleoside, e.g., a reverse transcriptase inhibitor (RTI), to the patient according to a continuous or an intermittent dosing schedule. RTIs include, but are not limited to, lamivudine (3TC), stavudine (d4T), emtricitabine (FTC), abacavir (ABC), tenofovir alafenamide, zidovudine (AZT), zalcitabine (ddC), didanosine (ddI), tenofovir disoproxil, adefovir dipivoxil, entecavir (ETV), telbivudine, and islatravir.